Solitary plasmacytoma: 10 years' experience at All India Institute of Medical Sciences, New Delhi.

Plasma cell dyscrasias account for 1% of all malignancies and 10% of hematological malignancies. About 5% of patients with a plasma cell dyscrasia present with either solitary bone plasmacytoma (SBP) or, less commonly, a soft tissue mass, extramedullary plasmacytoma (EMP) of monoclonal plasma cells. In this study we present the clinical features, management and outcome of 60 patients with solitary plasmacytoma, who constituted 5.6% of 1129 patients with plasma cell dyscrasias treated over a 10-year period at All India Institute of Medical Sciences. Median age was 49 years. Fifty-two had SBP and eight had EMP. Forty-nine (82%) patients received radiotherapy with or without surgical excision or chemotherapy. Five-year event-free survival (EFS) and overall survival (OS) were 45.5% and 91%, respectively. Median EFS and OS were 38 and 122 months, respectively. Five-year survival rates in patients who developed multiple myeloma and those who did not were 81% and 100%, respectively. The median time of progression to myeloma was 21 months.